Physician profile

John H Ferguson

Pulmonary Disease · Wheat Ridge, CO

NPI 1669682522

$39,961.78

in general payments reported to CMS, 2019-2025

45 companies · $14K in 2025

The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$17,550.00
Food and Beverage$1,599.08
Education$302.21

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Biosense Webster, INC. $16,359.53 2021-2025 Carto 3
Astrazeneca Pharmaceuticals LP $15,128.87 2019-2025 Fasenra, Breztri, Tezspire
Medical Device Business Services, INC. $3,696.15 2019-2024 Carto 3
Glaxosmithkline, LLC. $562.18 2019-2025 Nucala
Boehringer Ingelheim Pharmaceuticals, INC. $451.67 2019-2024 Ofev
Abbott Laboratories $432.80 2019-2025 Jot Dx
Insmed, INC. $361.39 2019-2025 Arikayce
Boston Scientific Corporation $299.07 2019-2022
Harmony Biosciences LLC $285.97 2023-2025 Wakix
Genzyme Corporation $228.94 2019-2023
Bayer Healthcare Pharmaceuticals INC. $159.42 2019-2023
Impulse Dynamics (USA) INC. $154.34 2023 Optimizer
Mallinckrodt Hospital Products INC. $126.11 2021-2023 Acthar
Actelion Pharmaceuticals US, INC. $123.95 2019-2025 Opsumit, Uptravi
Pfizer INC. $106.97 2019-2020
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Mylan Specialty L.P. $106.81 2019-2020
Abbvie INC. $93.64 2022-2023
Veran Medical Technologies, INC. $88.58 2019-2020
Genentech USA, INC. $85.35 2019
Edwards Lifesciences Corporation $84.58 2023
Merck Sharp & Dohme LLC $82.79 2024-2025 Winrevair
Inspire Medical Systems, INC. $80.64 2023 Inspire
Regeneron Healthcare Solutions, INC. $74.82 2019-2025 Dupixent
Grifols USA, LLC $58.80 2020-2023 Prolastin-C Liquid
Gilead Sciences, INC. $58.65 2021-2023 Veklury
Astellas Pharma US INC $56.13 2020-2021
Jazz Pharmaceuticals INC. $55.28 2021-2024
Angiodynamics, INC. $51.64 2024 Venacure 1470 Pro
E.R. Squibb & Sons, L.L.C. $45.20 2019-2022
Allergan, INC. $44.00 2020
Takeda Pharmaceuticals U.S.A., INC. $43.92 2020-2021
Novartis Pharmaceuticals Corporation $43.12 2019
United Therapeutics Corporation $39.91 2021-2022
Aerin Medical INC. $37.52 2025
Shire North American Group INC $30.98 2019
Liquidia Technologies, INC. $30.65 2025 Yutrepia
Inogen, INC. $28.91 2022
Philips North America LLC $26.86 2025 Vest Therapy Und
Cvrx, INC. $26.69 2023 Barostim Neo System
Sunovion Pharmaceuticals INC. $22.60 2020
Medtronic Vascular, INC. $20.62 2020
Mallinckrodt Enterprises LLC $20.06 2019
Medivance, INC. $17.66 2020
Lexicon Pharmaceuticals, INC. $15.19 2023 Inpefa
Janssen Pharmaceuticals, INC $12.82 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John H Ferguson

$39,961.78

in general payments reported 2019-2025

Years
2019-2025
Top company
Biosense Webster, INC.
Context
The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/167178/john-h-ferguson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.